317 related articles for article (PubMed ID: 37966552)
21. EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction.
Akalay I; Janji B; Hasmim M; Noman MZ; Thiery JP; Mami-Chouaib F; Chouaib S
Autophagy; 2013 Jul; 9(7):1104-6. PubMed ID: 23635487
[TBL] [Abstract][Full Text] [Related]
22. Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.
Peng H; Zhang Y; Zhou Z; Guo Y; Huang X; Westover KD; Zhang Z; Chen B; Hua Y; Li S; Xu R; Lin N; Peng B; Shen S
EBioMedicine; 2019 Aug; 46():105-118. PubMed ID: 31324602
[TBL] [Abstract][Full Text] [Related]
23. Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development.
Wei Q; Taskén K
Biochem J; 2022 Oct; 479(20):2219-2260. PubMed ID: 36305711
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-mesenchymal transition: Initiation by cues from chronic inflammatory tumor microenvironment and termination by anti-inflammatory compounds and specialized pro-resolving lipids.
Lee CH
Biochem Pharmacol; 2018 Dec; 158():261-273. PubMed ID: 30389404
[TBL] [Abstract][Full Text] [Related]
25. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis.
Hao Y; Baker D; Ten Dijke P
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195692
[TBL] [Abstract][Full Text] [Related]
26. Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression.
Kolijn K; Verhoef EI; Smid M; Böttcher R; Jenster GW; Debets R; van Leenders GJLH
Cancer Res; 2018 Aug; 78(16):4671-4679. PubMed ID: 29921693
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT).
Cho ES; Kang HE; Kim NH; Yook JI
Arch Pharm Res; 2019 Jan; 42(1):14-24. PubMed ID: 30649699
[TBL] [Abstract][Full Text] [Related]
28. The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer.
Ginnebaugh KR; Ahmad A; Sarkar FH
Expert Opin Ther Targets; 2014 Jul; 18(7):731-45. PubMed ID: 24758643
[TBL] [Abstract][Full Text] [Related]
29. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
30. Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.
Chockley PJ; Keshamouni VG
J Immunol; 2016 Aug; 197(3):691-8. PubMed ID: 27431984
[TBL] [Abstract][Full Text] [Related]
31. Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis.
Drak Alsibai K; Meseure D
Dev Dyn; 2018 Mar; 247(3):405-431. PubMed ID: 28691356
[TBL] [Abstract][Full Text] [Related]
32. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.
Dzobo K; Senthebane DA; Ganz C; Thomford NE; Wonkam A; Dandara C
Cells; 2020 Aug; 9(8):. PubMed ID: 32823711
[TBL] [Abstract][Full Text] [Related]
33. Roles of genetic and microenvironmental factors in cancer epithelial-to-mesenchymal transition and therapeutic implication.
Yang L; Shang Z; Long S; Wang N; Shan G; Zhang R
Exp Cell Res; 2018 Sep; 370(2):190-197. PubMed ID: 30075173
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.
Dong P; Xiong Y; Yue J; Hanley SJB; Watari H
Front Oncol; 2018; 8():386. PubMed ID: 30283733
[TBL] [Abstract][Full Text] [Related]
35. Tumor microenvironment remodeling plus immunotherapy could be used in mesenchymal-like tumor with high tumor residual and drug resistant rate.
Shen S; Liu X; Guo Q; Liang Q; Wu J; Guan G; Zou C; Zhu C; Yan Z; Liu T; Chen L; Cheng P; Cheng W; Wu A
Commun Biol; 2023 Dec; 6(1):1281. PubMed ID: 38110614
[TBL] [Abstract][Full Text] [Related]
36. Dynamic EMT: a multi-tool for tumor progression.
Brabletz S; Schuhwerk H; Brabletz T; Stemmler MP
EMBO J; 2021 Sep; 40(18):e108647. PubMed ID: 34459003
[TBL] [Abstract][Full Text] [Related]
37. Role of Epithelial to Mesenchymal Transition in Colorectal Cancer.
Lu J; Kornmann M; Traub B
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834263
[TBL] [Abstract][Full Text] [Related]
38. Crosstalk between Tumor Cells and Immune System Leads to Epithelial-Mesenchymal Transition Induction and Breast Cancer Progression.
Moradpoor R; Salimi M
Iran Biomed J; 2021 Jan; 25(1):1-7. PubMed ID: 33129234
[TBL] [Abstract][Full Text] [Related]
39. Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics.
Zhang J; Hu Z; Horta CA; Yang J
Semin Cancer Biol; 2023 Jan; 88():46-66. PubMed ID: 36521737
[TBL] [Abstract][Full Text] [Related]
40. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
Cai J; Cui Y; Yang J; Wang S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
